-

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

  • SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:40 p.m. EST
  • Cowen Annual Health Care Conference on Thursday, March 4, 2021 at 12:10 p.m. EST

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 14 days following the presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross
Investor Relations
(650) 425-8408

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English

Contacts

Jacquie Ross
Investor Relations
(650) 425-8408

More News From Gilead Sciences, Inc.

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union. Analyses fr...

Gilead Sciences Announces First Quarter Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Building on the strongest pipel...

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 12 at 2:20 PM Pacific Time RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 11:00 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 28 at 11:00 AM Eastern Time Goldman Sachs Annual Global Healthcare Conference on Tuesday, Ju...
Back to Newsroom